{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:34:49Z","timestamp":1792499689024,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2023,1,19]]},"DOI":"10.1038\/s41416-022-02028-6","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T19:02:51Z","timestamp":1668625371000},"page":"331-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["CXCR1\/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer"],"prefix":"10.1038","volume":"128","author":[{"given":"Geny","family":"Piro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annachiara","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Pizzol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubina","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Allegretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Aramini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Caggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Granitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Corbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3160-0634","authenticated-orcid":false,"given":"Rita Teresa","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-739X","authenticated-orcid":false,"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1378-4962","authenticated-orcid":false,"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"2028_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"2028_CR2","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828\u201333.","journal-title":"J Immunother"},{"key":"2028_CR3","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer. N. Engl J Med. 2012;366:2455\u201365.","journal-title":"N. Engl J Med"},{"key":"2028_CR4","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","volume":"5","author":"EM O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma. JAMA Oncol. 2019;5:1431.","journal-title":"JAMA Oncol"},{"key":"2028_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41416-019-0479-5","volume":"121","author":"E Karamitopoulou","year":"2019","unstructured":"Karamitopoulou E. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br J Cancer. 2019;121:5\u201314.","journal-title":"Br J Cancer"},{"key":"2028_CR6","doi-asserted-by":"crossref","unstructured":"Li R, He Y, Zhang H, Wang J, Liu X, Liu H, et al. Identification and validation of immune molecular subtypes in pancreatic ductal adenocarcinoma: implications for prognosis and immunotherapy. Front Immunol. 2021;12:2829.","DOI":"10.3389\/fimmu.2021.690056"},{"key":"2028_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1117-9","volume":"18","author":"X Liu","year":"2019","unstructured":"Liu X, Xu J, Zhang B, Liu J, Liang C, Meng Q, et al. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Mol Cancer. 2019;18:184.","journal-title":"Mol Cancer"},{"key":"2028_CR8","doi-asserted-by":"publisher","first-page":"6174","DOI":"10.1111\/febs.15726","volume":"288","author":"S Yan","year":"2021","unstructured":"Yan S, Wan G. Tumor\u2010associated macrophages in immunotherapy. FEBS J. 2021;288:6174\u201386.","journal-title":"FEBS J"},{"key":"2028_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31675-0","volume":"8","author":"D Powell","year":"2018","unstructured":"Powell D, Lou M, Barros Becker F, Huttenlocher A. Cxcr1 mediates recruitment of neutrophils and supports proliferation of tumor-initiating astrocytes in vivo. Sci Rep. 2018;8:13285.","journal-title":"Sci Rep."},{"key":"2028_CR10","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","volume":"22","author":"C Alfaro","year":"2016","unstructured":"Alfaro C, Teijeira A, O\u00f1ate C, P\u00e9rez G, Sanmamed MF, Andueza MP, et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res. 2016;22:3924\u201336.","journal-title":"Clin Cancer Res"},{"key":"2028_CR11","doi-asserted-by":"crossref","unstructured":"Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6:237ra67.","DOI":"10.1126\/scitranslmed.3007974"},{"key":"2028_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41591-020-0873-9","volume":"26","author":"Z Bakouny","year":"2020","unstructured":"Bakouny Z, Choueiri TK. IL-8 and cancer prognosis on immunotherapy. Nat Med. 2020;26:650\u20131.","journal-title":"Nat Med"},{"key":"2028_CR13","doi-asserted-by":"crossref","unstructured":"Wu L, Xie S, Wang L, Li J, Han L, Qin B, et al. The ratio of IP10 to IL-8 in plasma reflects and predicts the response of patients with lung cancer to anti-PD-1 immunotherapy combined with chemotherapy. Front Immunol. 2021;12:1113.","DOI":"10.3389\/fimmu.2021.665147"},{"key":"2028_CR14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26:688\u201392.","journal-title":"Nat Med"},{"key":"2028_CR15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","volume":"26","author":"KC Yuen","year":"2020","unstructured":"Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med. 2020;26:693\u20138.","journal-title":"Nat Med"},{"key":"2028_CR16","doi-asserted-by":"publisher","first-page":"215722","DOI":"10.1016\/j.canlet.2022.215722","volume":"539","author":"P Li","year":"2022","unstructured":"Li P, Rozich N, Wang J, Wang J, Xu Y, Herbst B, et al. Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. Cancer Lett. 2022;539:215722.","journal-title":"Cancer Lett"},{"key":"2028_CR17","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1158\/2326-6066.CIR-16-0188","volume":"4","author":"T Chao","year":"2016","unstructured":"Chao T, Furth EE, Vonderheide RH. CXCR2-dependent accumulation of tumor-associated neutrophils regulates T-cell immunity in pancreatic ductal adenocarcinoma. Cancer Immunol Res. 2016;4:968\u201382.","journal-title":"Cancer Immunol Res"},{"key":"2028_CR18","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-20-1319","volume":"27","author":"A Teijeira","year":"2021","unstructured":"Teijeira A, Garasa S, Ochoa MC, Villalba M, Olivera I, Cirella A, et al. IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy. Clin Cancer Res. 2021;27:2383\u201393.","journal-title":"Clin Cancer Res"},{"key":"2028_CR19","doi-asserted-by":"crossref","unstructured":"Horowitz NB, Mohammad I, Moreno-Nieves UY, Koliesnik I, Tran Q, Sunwoo JB. Humanized mouse models for the advancement of innate lymphoid cell-based cancer immunotherapies. Front Immunol. 2021;12:977.","DOI":"10.3389\/fimmu.2021.648580"},{"key":"2028_CR20","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.it.2018.07.001","volume":"39","author":"P de La Rochere","year":"2018","unstructured":"de La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized mice for the study of immuno-oncology. Trends Immunol. 2018;39:748\u201363.","journal-title":"Trends Immunol"},{"key":"2028_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nri2017","volume":"7","author":"LD Shultz","year":"2007","unstructured":"Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7:118\u201330.","journal-title":"Nat Rev Immunol"},{"key":"2028_CR22","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.1158\/0008-5472.CAN-16-1201","volume":"76","author":"L Ireland","year":"2016","unstructured":"Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quaranta V, et al. Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors. Cancer Res. 2016;76:6851\u201363.","journal-title":"Cancer Res"},{"key":"2028_CR23","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.celrep.2018.10.051","volume":"25","author":"TDD Somerville","year":"2018","unstructured":"Somerville TDD, Xu Y, Miyabayashi K, Tiriac H, Cleary CR, Maia-Silva D, et al. TP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma. Cell Rep. 2018;25:1741\u201355.e7.","journal-title":"Cell Rep."},{"key":"2028_CR24","doi-asserted-by":"publisher","first-page":"e002876","DOI":"10.1136\/jitc-2021-002876","volume":"9","author":"C Carbone","year":"2021","unstructured":"Carbone C, Piro G, Agostini A, Delfino P, de Sanctis F, Nasca V, et al. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer. J Immunother Cancer. 2021;9:e002876.","journal-title":"J Immunother Cancer"},{"key":"2028_CR25","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/j.celrep.2019.07.068","volume":"28","author":"D di Mitri","year":"2019","unstructured":"di Mitri D, Mirenda M, Vasilevska J, Calcinotto A, Delaleu N, Revandkar A, et al. Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer. Cell Rep. 2019;28:2156\u201368.e5.","journal-title":"Cell Rep."},{"key":"2028_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1158\/1535-7163.MCT-19-0270","volume":"19","author":"R Santoro","year":"2020","unstructured":"Santoro R, Zanotto M, Simionato F, Zecchetto C, Merz V, Cavallini C, et al. Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer. Mol Cancer Ther. 2020;19:247\u201357.","journal-title":"Mol Cancer Ther"},{"key":"2028_CR27","doi-asserted-by":"crossref","unstructured":"Santoro R, Zanotto M, Carbone C, Piro G, Tortora G, Melisi D. MEKK3 sustains EMT and stemness in pancreatic cancer by regulating YAP and TAZ transcriptional activity. Anticancer Res. 2018;38:1937\u201346.","DOI":"10.21873\/anticanres.12431"},{"key":"2028_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1476-5381.2011.01566.x","volume":"165","author":"R Bertini","year":"2012","unstructured":"Bertini R, Barcelos LS, Beccari AR, Cavalieri B, Moriconi A, Bizzarri C, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1\/CXCR2 non-competitive allosteric inhibitor. Br J Pharm. 2012;165:436\u201354.","journal-title":"Br J Pharm"},{"key":"2028_CR29","first-page":"35","volume":"17","author":"A Garau","year":"2006","unstructured":"Garau A, Bertini R, Mosca M, Bizzarri C, Anacardio R, Triulzi S, et al. Development of a systemically-active dual CXCR1\/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat. Eur Cytokine Netw. 2006;17:35\u201341.","journal-title":"Eur Cytokine Netw"},{"key":"2028_CR30","first-page":"e100115","volume":"4","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMJ Open Sci. 2020;4:e100115.","journal-title":"BMJ Open Sci."},{"key":"2028_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47\u201352.","journal-title":"Nature"},{"key":"2028_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3389\/fimmu.2016.00575","volume":"7","author":"AA Zachary","year":"2016","unstructured":"Zachary AA, Leffell MS. HLA mismatching strategies for solid organ transplantation\u2014a balancing act. Front Immunol. 2016;7:575.","journal-title":"Front Immunol"},{"key":"2028_CR33","doi-asserted-by":"publisher","first-page":"e1326442","DOI":"10.1080\/2162402X.2017.1326442","volume":"6","author":"A Facciabene","year":"2017","unstructured":"Facciabene A, de Sanctis F, Pierini S, Reis ES, Balint K, Facciponte J, et al. Local endothelial complement activation reverses endothelial quiescence, enabling T-cell homing, and tumor control during T-cell immunotherapy. Oncoimmunology. 2017;6:e1326442.","journal-title":"Oncoimmunology."},{"key":"2028_CR34","doi-asserted-by":"crossref","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417\u20139.","DOI":"10.1038\/nmeth.4197"},{"key":"2028_CR35","first-page":"e140","volume":"43","author":"S Tarazona","year":"2015","unstructured":"Tarazona S, Furi\u00f3-Tar\u00ed P, Turr\u00e0 D, di Pietro A, Nueda MJ, Ferrer A, et al. Data quality aware analysis of differential expression in RNA-seq with NOISeq R\/Bioc package. Nucleic Acids Res. 2015;43:e140.","journal-title":"Nucleic Acids Res"},{"key":"2028_CR36","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90\u20137.","journal-title":"Nucleic Acids Res"},{"key":"2028_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48663-7","volume":"9","author":"D Filippini","year":"2019","unstructured":"Filippini D, Agosto SD, Delfino P, Simbolo M, Piro G, Rusev B, et al. Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. Sci Rep. 2019;9:12286.","journal-title":"Sci Rep."},{"key":"2028_CR38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581:100\u20135.","journal-title":"Nature."},{"key":"2028_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cytogfr.2016.08.002","volume":"31","author":"Q Liu","year":"2016","unstructured":"Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T, et al. The CXCL8-CXCR1\/2 pathways in cancer. Cytokine Growth Factor Rev. 2016;31:61\u201371.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2028_CR40","doi-asserted-by":"publisher","first-page":"14428","DOI":"10.18632\/oncotarget.14803","volume":"8","author":"DM Kemp","year":"2017","unstructured":"Kemp DM, Pidich A, Larijani M, Jonas R, Lash E, Sato T, et al. Ladarixin, a dual CXCR1\/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. Oncotarget. 2017;8:14428\u201342.","journal-title":"Oncotarget."},{"key":"2028_CR41","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1084\/jem.167.4.1364","volume":"167","author":"J van Damme","year":"1988","unstructured":"van Damme J, van Beeumen J, Opdenakker G, Billiau A. A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity. J Exp Med. 1988;167:1364\u201376.","journal-title":"J Exp Med"},{"key":"2028_CR42","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.4049\/jimmunol.164.7.3862","volume":"164","author":"R Bonecchi","year":"2000","unstructured":"Bonecchi R, Facchetti F, Dusi S, Luini W, Lissandrini D, Simmelink M, et al. Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes. J Immunol. 2000;164:3862\u20139.","journal-title":"J Immunol"},{"key":"2028_CR43","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1124\/mol.108.045146","volume":"74","author":"M Gouwy","year":"2008","unstructured":"Gouwy M, Struyf S, Noppen S, Schutyser E, Springael JY, Parmentier M, et al. Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events. Mol Pharm. 2008;74:485\u201395.","journal-title":"Mol Pharm"},{"key":"2028_CR44","doi-asserted-by":"publisher","first-page":"2998.","DOI":"10.3390\/ijms22062998","volume":"22","author":"J Shi","year":"2021","unstructured":"Shi J, Song X, Traub B, Luxenhofer M, Kornmann M. Involvement of IL-4, IL-13 and their receptors in pancreatic cancer. Int J Mol Sci. 2021;22:2998.","journal-title":"Int J Mol Sci"},{"key":"2028_CR45","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","volume":"22","author":"C Alfaro","year":"2016","unstructured":"Alfaro C, Teijeira A, O\u00f1ate C, P\u00e9rez G, Sanmamed MF, Andueza MP, et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res. 2016;22:3924\u201336.","journal-title":"Clin Cancer Res"},{"key":"2028_CR46","doi-asserted-by":"crossref","unstructured":"Foucher ED, Ghigo C, Chouaib S, Galon J, Iovanna J, Olive D. Pancreatic ductal adenocarcinoma: a strong imbalance of good and bad immunological cops in the tumor microenvironment. Front Immunol. 2018;9:1044.","DOI":"10.3389\/fimmu.2018.01044"},{"key":"2028_CR47","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11:5365\u201386.","journal-title":"Theranostics."},{"key":"2028_CR48","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.immuni.2019.01.002","volume":"50","author":"JM Adrover","year":"2019","unstructured":"Adrover JM, del Fresno C, Crainiciuc G, Cuartero MI, Casanova-Acebes M, Weiss LA, et al. A neutrophil timer coordinates immune defense and vascular protection. Immunity. 2019;50:390\u2013402.e10.","journal-title":"Immunity."},{"key":"2028_CR49","doi-asserted-by":"publisher","first-page":"e003495","DOI":"10.1136\/jitc-2021-003495","volume":"9","author":"LA Mittmann","year":"2021","unstructured":"Mittmann LA, Haring F, Schaub\u00e4cher JB, Hennel R, Smiljanov B, Zuchtriegel G, et al. Uncoupled biological and chronological aging of neutrophils in cancer promotes tumor progression. J Immunother Cancer. 2021;9:e003495.","journal-title":"J Immunother Cancer"},{"key":"2028_CR50","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41416-019-0678-0","volume":"122","author":"J Bhimani","year":"2020","unstructured":"Bhimani J, Ball K, Stebbing J. Patient-derived xenograft models\u2014the future of personalised cancer treatment. Br J Cancer. 2020;122:601\u20132.","journal-title":"Br J Cancer"},{"key":"2028_CR51","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3390\/cancers12041025","volume":"12","author":"WN Liu","year":"2020","unstructured":"Liu WN, Fong SY, Tan WWS, Tan SY, Liu M, Cheng JY, et al. Establishment and characterization of humanized mouse NPC-PDX model for testing immunotherapy. Cancers. 2020;12:1025.","journal-title":"Cancers"},{"key":"2028_CR52","doi-asserted-by":"crossref","unstructured":"Stripecke R, M\u00fcnz C, Schuringa JJ, Bissig K, Soper B, Meeham T, et al. Innovations, challenges, and minimal information for standardization of humanized mice. EMBO Mol Med. 2020;12:e8662.","DOI":"10.15252\/emmm.201708662"},{"key":"2028_CR53","doi-asserted-by":"crossref","unstructured":"Li R, He Y, Zhang H, Wang J, Liu X, Liu H, et al. Identification and validation of immune molecular subtypes in pancreatic ductal adenocarcinoma: implications for prognosis and immunotherapy. Front Immunol. 2021;12:2829.","DOI":"10.3389\/fimmu.2021.690056"},{"key":"2028_CR54","first-page":"6","volume":"6","author":"KY Li","year":"2020","unstructured":"Li KY, Yuan JL, Trafton D, Wang JX, Niu N, Yuan CH, et al. Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. Chronic Dis Transl Med. 2020;6:6\u201317.","journal-title":"Chronic Dis Transl Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02028-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02028-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02028-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T14:07:15Z","timestamp":1675951635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02028-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1,19]]}},"alternative-id":["2028"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-02028-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"assertion":[{"value":"19 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MDP, RN, MA and AAr are employees of Domp\u00e9 Farmaceutici S.p.A. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"In vivo experiments were conducted in accordance with the guidelines of the Institutional OPBA and the Italian Ministry of Health Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The study protocol was approved by the Institutional Board of the University of Verona, Verona, Italy. The study was conducted according to the principles of the Declaration of Helsinki and was performed in compliance with Good Clinical Practice guidelines. Written informed consent was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}